 The FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to Decibel Therapeutics Inc NASDAQ: DBTX lead gene therapy product candidate, DB-OTO, for otoferlin-related congenital hearing loss. The Company looks forward to initiating a Phase 12 trial of DB-OTO in pediatric patients in 2022. 